Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

August 23, 2023

Study Completion Date

February 2, 2024

Conditions
Dry Eye Syndromes
Interventions
DRUG

SCAI-001 0.01% eyedrop

BID for 12weeks

DRUG

SCAI-001 0.02% eyedrop

BID for 12weeks

DRUG

Restasis 0.05% eyedrop

BID for 12weeks

Trial Locations (11)

Unknown

The Catholic University of korea, Bucheon ST.Mary's Hospital, Bucheon-si

Inje University Busan Paik Hospital, Busan

Pusan National Univ. Hospital, Busan

Kyungpook National University Hospital, Daegu

Asan Medical Center, Seoul

Hallym University Kangnam Sacred Heart Hospital, Seoul

Kangbuk Samsung Hospital, Seoul

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Yonsei University Wonju Severance Christian Hospital, Wŏnju

Pusan National University Yangsan Hospital, Yangsan

All Listed Sponsors
lead

SCAI Therapeutics

INDUSTRY